Standalone Audited Financial Results for the Quarter and Financial Year Ended on 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals reported FY25 revenue from operations of Rs. 15,169.15 lakhs, up about 6.8% from Rs. 14,196.65 lakhs in FY24. Profit after tax rose to Rs. 3,206.06 lakhs from Rs. 2,597.73 lakhs, a growth of roughly 23.4%, with EPS climbing to Rs. 72.65 from Rs. 58.86. Q4 FY25 revenue stood at Rs. 4,104.69 lakhs (vs Rs. 3,884.20 lakhs) and Q4 PAT at Rs. 853.66 lakhs (vs Rs. 788.21 lakhs). The Board has recommended a dividend of Rs. 21.80 per share (180%) on 44.13 lakh equity shares. Operating cash flow jumped sharply to Rs. 2,790.60 lakhs from Rs. 812.38 lakhs. The auditor issued an unmodified (clean) opinion on the financial statements.
Strong PAT growth, healthy dividend, and a clean audit opinion are positive for shareholders. The sharply higher operating cash flow and virtually debt-free balance sheet further support the company's financial strength.